163 related articles for article (PubMed ID: 8210646)
1. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: experience of the BFM study 86.
Ludwig WD; Harbott J; Bartram CR; Komischke B; Sperling C; Teichmann JV; Seibt-Jung H; Notter M; Odenwald E; Nehmer A
Recent Results Cancer Res; 1993; 131():269-82. PubMed ID: 8210646
[No Abstract] [Full Text] [Related]
2. Incidence, clinical and laboratory features, and prognostic significance of immunophenotypic subgroups in acute lymphoblastic leukemia: the GEIL experience.
Garand R; Béné MC
Recent Results Cancer Res; 1993; 131():283-95. PubMed ID: 8210647
[No Abstract] [Full Text] [Related]
3. [Incidence, clinical markers and prognostic significance of immunologic subtypes of acute lymphoblastic leukemia (ALL) in children: experiences of the ALL-BFM 83 and 86 studies].
Ludwig WD; Teichmann JV; Sperling C; Komischke B; Ritter J; Reiter A; Odenwald E; Sauter S; Riehm H
Klin Padiatr; 1990; 202(4):243-52. PubMed ID: 2203938
[TBL] [Abstract][Full Text] [Related]
4. Childhood acute lymphoblastic leukemia immunophenotypes and their prognostic significance: experience of the IGCI-study in 389 children. International Society for Chemo-immunotherapy (IGCI-Vienna) Cooperative Group.
Holowiecki J; Koehler M; Zintl Z; Kardos G; Lutz D; Krzemien S; Rewesz T; Brugiatelli M; Callea V; Kachel L
Leuk Lymphoma; 1992 Jun; 7(3):225-34. PubMed ID: 1477650
[TBL] [Abstract][Full Text] [Related]
5. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: the experience of the AIEOP Cooperative Study. Associazione Italiana Ematologia Oncologia Pediatrica.
Basso G; Rondelli R; Putti MC; Cantù Rajnoldi A; Granchi D; Cocito MG; Saitta M; Santostasi T; Guglielmi C; Lippi A
Recent Results Cancer Res; 1993; 131():297-307. PubMed ID: 8210648
[No Abstract] [Full Text] [Related]
6. Use of clinical and laboratory features to define prognostic subgroups in B-precursor acute lymphoblastic leukemia: experience of the Pediatric Oncology Group.
Borowitz MJ; Carroll AJ; Shuster JJ; Look AT; Behm FG; Pullen DJ; Land VJ; Steuber P; Crist WM
Recent Results Cancer Res; 1993; 131():257-67. PubMed ID: 8210645
[No Abstract] [Full Text] [Related]
7. Immunologic subclassification of acute lymphoblastic leukemia in childhood and prognosis (modified BFM protocol).
Zintl F; Häfer R
Haematol Blood Transfus; 1989; 32():109-12. PubMed ID: 2696675
[No Abstract] [Full Text] [Related]
8. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies.
Putti MC; Rondelli R; Cocito MG; Aricó M; Sainati L; Conter V; Guglielmi C; Cantú-Rajnoldi A; Consolini R; Pession A; Zanesco L; Masera G; Biondi A; Basso G
Blood; 1998 Aug; 92(3):795-801. PubMed ID: 9680347
[TBL] [Abstract][Full Text] [Related]
9. Molecular and clinical prognostic factors in BFM-treated childhood acute lymphoblastic leukemia patients: a single institution series.
Ruano D; Diaz MA; Tutor O; Garcia-Sanchez F; Martinez P; Madero L
Haematologica; 2000 Aug; 85(8):877-8. PubMed ID: 10942942
[No Abstract] [Full Text] [Related]
10. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotypic classification of acute lymphoblastic leukaemia.
Ludwig WD; Raghavachar A; Thiel E
Baillieres Clin Haematol; 1994 Jun; 7(2):235-62. PubMed ID: 7803900
[No Abstract] [Full Text] [Related]
12. Clinical significance of cytogenetic studies in childhood acute lymphoblastic leukemia: experience of the BFM trials.
Harbott J; Ritterbach J; Ludwig WD; Bartram CR; Reiter A; Lampert F
Recent Results Cancer Res; 1993; 131():123-32. PubMed ID: 8210633
[No Abstract] [Full Text] [Related]
13. DNA aneuploidy in childhood acute lymphoblastic leukemia: relation to clinical determinants and prognosis within four consecutive BFM trials.
Hiddemann W; Harbott J; Ludwig WD; Ritter J; Nehmer A; Reiter A; Kolkmeyer A; Laing T; Riehm H
Recent Results Cancer Res; 1993; 131():113-21. PubMed ID: 8210632
[No Abstract] [Full Text] [Related]
14. Clinicopathological features and prognostic implications of immunophenotypic subgroups in childhood ALL: experience of the BFM-ALL Study 83.
Ludwig WD; Seibt-Jung H; Teichmann JV; Komischke B; Gatzke A; Gassner G; Odenwald E; Hofmann J; Riehm H
Haematol Blood Transfus; 1989; 32():51-7. PubMed ID: 2696693
[No Abstract] [Full Text] [Related]
15. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment results of Polish pediatric and adolescent patients enrolled in the ALL IC-BFM 2002 trial.
Kowalczyk JR; Zawitkowska J; Lejman M; Drabko K; Samardakiewicz M; Matysiak M; Romiszewski M; Balwierz W; Ćwiklińska M; Kazanowska B; Owoc-Lempach J; Wachowiak J; Derwich K; Adamkiewicz-Drożyńska E; Niedźwiecki M; Trelińska J; Młynarski W; Wysocki M; Kołtan A; Szczepański T; Krawczuk-Rybak M; Kitszel A; Wieczorek M; Urasiński T; Ociepa T; Sobol-Milejska G; Mizia-Malarz A; Karolczyk G; Stary J
Am J Hematol; 2019 Nov; 94(11):E307-E310. PubMed ID: 31432528
[No Abstract] [Full Text] [Related]
17. CD34 antigen expression in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Azuma E; Umemoto M; Kubo M; Ohta Y; Zhang SL; Komada Y; Ito M; Sakurai M
Cancer; 1991 Mar; 67(6):1565-9. PubMed ID: 1705862
[TBL] [Abstract][Full Text] [Related]
18. MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen.
zur Stadt U; Harms DO; Schlüter S; Schrappe M; Goebel U; Spaar H; Janka G; Kabisch H
Leukemia; 2001 Feb; 15(2):283-5. PubMed ID: 11236947
[No Abstract] [Full Text] [Related]
19. Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.
Yamaji K; Okamoto T; Yokota S; Watanabe A; Horikoshi Y; Asami K; Kikuta A; Hyakuna N; Saikawa Y; Ueyama J; Watanabe T; Okada M; Taga T; Kanegane H; Kogawa K; Chin M; Iwai A; Matsushita T; Shimomura Y; Hori T; Tsurusawa M;
Pediatr Blood Cancer; 2010 Dec; 55(7):1287-95. PubMed ID: 20535816
[TBL] [Abstract][Full Text] [Related]
20. [The treatment of acute lymphoblastic leukemias in adults].
Savchenko VG; Parovichnikova EN; Isaev VG; Kliasova GA; Kucher RA; Sokolov AN; Sarkisian GP; Gal'tseva IV; Ol'shanskaia IuV; Ustinova EN; Gribanova EO; Kokhno AV; Tikhonova LIu; Maslova ER
Ter Arkh; 1997; 69(7):5-11. PubMed ID: 9424759
[No Abstract] [Full Text] [Related]
[Next] [New Search]
